Memantin Stada

Memantine, the active ingredient in Memantin Stada, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition, function and behavior.

GNH USA supplies Memantin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Memantin Stada is an NMDA receptor antagonist used in the management of Alzheimer’s disease and its related symptoms.

Alzheimer’s disease (moderate to severe): improves cognitive function and daily activities. Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression. Functional decline in Alzheimer’s disease: helps maintain independence in routine tasks.

Memantin Stada may cause a range of adverse reactions. Most are mild and reversible, but rare serious events have been reported.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: temporary disorientation. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring medical attention. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Hepatic dysfunction: abnormal liver enzyme elevations. - Cardiac arrhythmia: irregular heart rhythm. - Suicidal thoughts: emergence of depressive ideation. - Severe skin reactions: toxic epidermal necrolysis.

Before initiating Memantin Stada, clinicians should consider several safety aspects.

Renal impairment: adjust dose or monitor renal function. History of seizures: use with caution and monitor for convulsions. Cardiovascular disease: monitor blood pressure regularly. Concurrent NMDA antagonists: avoid additive neurotoxicity. Pregnancy and lactation: safety unknown; avoid unless benefit outweighs risk. Store at ambient temperature: keep in original container, protect from moisture.

Memantin Stada can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Other NMDA antagonists (e.g., ketamine): heightened risk of central nervous system effects. - Strong CYP3A4 inducers (e.g., carbamazepine): may reduce memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may blunt cognitive benefits. - Diuretics: can increase risk of hypotension. - Antihypertensives: monitor blood pressure for additive lowering effect.